{"slug":"quest-diagnostics","name":"퀘스트 다이아그노스틱스","name_en":"Quest Diagnostics Incorporated","ticker":"DGX","updated_at":"2026-09-24T04:50:47.861951+00:00","canonical":"https://valuechain.wiki/quest-diagnostics","citable":"밸류체인 그래프 기준 퀘스트 다이아그노스틱스의 직접 연결 기업은 2곳(관계 기준 공급 1·매출 1)이고, 사슬을 2차까지 넓히면 4곳에 닿는다. 링크의 근거 출처는 7건이며 그중 1차공시가 1건이다 (valuechain.wiki, 2026-09-24 기준).","citable_en":"Per the valuechain.wiki graph, Quest Diagnostics Incorporated is directly linked to 2 companies (1 supply, 1 revenue relationships) and reaches 4 companies within two hops; the links are backed by 7 dated sources, 1 of them primary filings (as of 2026-09-24).","kicker":"진단검사 네트워크","kicker_en":"Diagnostic testing network","lead":"의사, 병원, 보험사와 정부기관에 임상검사와 진단정보 서비스를 제공해 돈을 번다. 검사 장비와 시약, 고객 주문부터 청구까지 이어지는 IT 시스템에 비용을 쓰며, 지역 검사실과 전문검사 자산 인수로 검사량과 서비스 범위를 넓힌다.","lead_en":"Quest earns revenue by providing clinical testing and diagnostic information services to physicians, hospitals, health plans, and government agencies. It spends on laboratory instruments, reagents, and order-to-cash technology, while acquiring regional laboratories and specialized testing assets to expand volume and capabilities.","categories":[{"key":"healthcare-providers-diagnostics","ko":"의료기관·진단 서비스","en":"Healthcare Providers & Diagnostic Services","theme":"life-sciences","theme_ko":"바이오·헬스","theme_en":"Biopharma & Life Sciences","theme_kind":"sector","primary":true}],"segments":{"parts":[{"name":"진단정보서비스","note":"FY2025 매출 107억8500만달러. 의사 검사실 서비스 71%, 병원 검사실 서비스 18%, 기타 진단정보서비스 9%로 구성된다."},{"name":"진단솔루션","note":"FY2025 매출 2억5000만달러. 보험사 위험평가와 의료 IT 솔루션을 제공한다."}],"total":"FY2025 순매출 110억3500만달러","track":"C"},"segments_en":{"parts":[{"name":"Diagnostic Information Services","note":"FY2025 revenue was $10.785 billion, comprising physician lab services at 71%, hospital lab services at 18%, and other DIS at 9% of total net revenues."},{"name":"Diagnostic Solutions","note":"FY2025 revenue was $250 million from insurer risk assessment and healthcare IT solutions."}],"total":"FY2025 net revenues of $11.035 billion"},"returns_yearly":{"2021":47.9,"2022":-7.8,"2023":-10.1,"2024":11.8,"2025":17.2,"2026":38.4},"return_asof":"2026-09-04","value_chain":{"leading":[{"slug":"unitedhealth-group","name":"유나이티드헬스 그룹","name_en":"UnitedHealth Group Incorporated","tier":1,"returns_yearly":{"2021":45.2,"2022":6.9,"2023":0.8,"2024":-2.4,"2025":-33.1,"2026":21.9}}],"benefiting":[{"slug":"siemens-ag","name":"지멘스","name_en":"Siemens AG","tier":1,"returns_yearly":{"2021":12.2,"2022":5.1,"2023":20.1,"2024":28,"2025":26.4,"2026":8.4}},{"slug":"siemens-energy","name":"Siemens Energy","name_en":"Siemens Energy","tier":2,"returns_yearly":{"2021":-35.4,"2022":-2.7,"2023":-27,"2024":314.2,"2025":149.9,"2026":1.8}},{"slug":"siemens-eda","name":"Siemens EDA","name_en":"Siemens EDA","tier":2,"returns_yearly":null}],"analysis":"진단검사 네트워크 기업. 2026년 +38.4%다. 수요단(평균 +21.9%)·본주(+38.4%)·공급단(평균 +8.6%)이 비슷한 보폭이다. 전파가 한 바퀴 돈 동조 국면이라, 다음 구간은 사슬 방향보다 개별 실적이 가른다. 연결 노드 중 가장 앞선 곳은 유나이티드헬스 그룹(+21.9%), 가장 처진 곳은 지멘스(+8.6%)다. 격차가 사슬 논리로 설명되면 후자가 다음 전파 후보이고, 설명되지 않으면 그 연결 자체를 다시 봐야 한다.","analysis_en":"Quest Diagnostics Incorporated operates across Diagnostic testing network. It is +38.4% in 2026. Demand side (avg +21.9%), the stock (+38.4%) and supply side (avg +8.6%) are moving in step. Propagation has completed a lap, so the next leg depends on individual results more than chain direction. Among connected nodes the furthest ahead is UnitedHealth Group Incorporated (+21.9%) and the furthest behind is Siemens AG (+8.6%). If chain logic explains the gap, the laggard is the next propagation candidate; if not, the link itself deserves a second look. It spends on laboratory instruments, reagents, and order-to-cash technology, while acquiring regional laboratories and specialized testing assets to expand volume and capabilities.","analysis_asof":"2026-09-04"},"edges":[{"direction":"investment","counterparty":"Spectra Laboratories","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2026-02-26","basis":"Spectra Laboratories 임상검사·투석용수 검사 자산 인수 현금대가","value":84000000,"period":"FY2025","basis_en":"Cash consideration for acquired Spectra Laboratories clinical and dialysis-water testing assets","qualifier":null},"note":"퀘스트는 Fresenius Medical Care가 보유한 Spectra Laboratories의 임상검사와 투석용수 검사 자산을 2025년에 인수했다. 두 차례 종결된 자산의 총 현금 대가는 8400만달러였다.","note_en":"Quest acquired clinical testing and dialysis-related water testing assets from Fresenius Medical Care's Spectra Laboratories in 2025. Aggregate cash consideration for the businesses was $84 million.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm","title":"QUEST DIAGNOSTICS INC 10-K (2026-02-26)","title_en":"QUEST DIAGNOSTICS INC 10-K (2026-02-26)","excerpt":"인수한 사업의 총 현금대가로 8400만달러를 지급했다.","excerpt_en":"paid $84 million of aggregate cash consideration."},{"stance":"confirms","publisher":"Quest Diagnostics","publisher_en":"Quest Diagnostics","kind":"ir","lang":"en","published_at":"2025-08-05","url":"https://s2.q4cdn.com/390454341/files/doc_news/Quest-Diagnostics-Completes-Acquisition-of-Clinical-Testing-Assets-from-Fresenius-Medical-Care-2025.pdf","title":"Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care","title_en":"Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care","excerpt":"Fresenius Medical Care의 Spectra Laboratories 임상검사 자산 인수를 완료했다.","excerpt_en":"completed its previously announced acquisition of select clinical testing assets."}]},{"direction":"revenue","counterparty":"유나이티드헬스 그룹","counterparty_slug":"unitedhealth-group","confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2026-06-08","basis":"UnitedHealthcare 우선 검사실 네트워크에서 발생하는 퀘스트의 상대별 매출","value":null,"period":"2026 Preferred Lab Network","basis_en":"Quest revenue attributable to participation in UnitedHealthcare's Preferred Lab Network","qualifier":"confirmed_no_disclosed_value"},"note":"유나이티드헬스 그룹의 보험 자회사 UnitedHealthcare는 퀘스트를 2026년 Preferred Lab Network의 종합검사 제공자로 선정했다. 10-K도 이 네트워크 참여를 직접 확인하지만 상대별 매출은 공개하지 않았다.","note_en":"UnitedHealth Group's insurance subsidiary, UnitedHealthcare, selected Quest as a full-test-menu provider in its 2026 Preferred Lab Network. Quest's 10-K confirms participation, but revenue attributable to this payer is not disclosed.","sources":[{"stance":"confirms","publisher":"유나이티드헬스케어","publisher_en":"UnitedHealthcare","kind":"ir","lang":"en","published_at":"2026-06-08","url":"https://www.uhcprovider.com/content/dam/provider/docs/public/reports/Preferred-Lab-Network-Frequently-Asked-Questions.pdf","title":"선호 검사기관 네트워크 자주 묻는 질문","title_en":"Preferred Lab Network Frequently Asked Questions","excerpt":"2026년 7월부터 퀘스트가 종합검사 제공자로 참여한다.","excerpt_en":"Quest Diagnostics, Inc."},{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm","title":"QUEST DIAGNOSTICS INC 10-K (2026-02-26)","title_en":"QUEST DIAGNOSTICS INC 10-K (2026-02-26)","excerpt":"UnitedHealthcare Preferred Lab Network가 퀘스트를 참여 사업자로 선정했다고 공시했다.","excerpt_en":"The UnitedHealthcare Preferred Lab Network, which chose us to participate."}]},{"direction":"revenue","counterparty":"미국 질병통제예방센터","counterparty_slug":null,"confidence":"high","metric":{"type":"contract_value","unit":"USD","as_of":"2025-04-23","basis":"CDC의 퀘스트 검사·데이터 제공 계약 금액","value":null,"period":"2024-2029 contract term","basis_en":"Value of CDC testing and laboratory-data contracts attributable to Quest","qualifier":"confirmed_no_disclosed_value"},"note":"CDC는 퀘스트를 포함한 검사기관들과 5년 계약을 맺어 200개가 넘는 신고대상 질환의 검사 데이터와 비상시 검사 역량을 확보했다. 퀘스트 10-K는 이 계약을 바탕으로 H5 조류인플루엔자 검사를 출시했다고 확인한다.","note_en":"The CDC awarded five-year contracts to Quest and other laboratories for data covering more than 200 reportable conditions and surge testing capacity. Quest's 10-K confirms that a CDC preparedness contract supported the launch of its H5 avian influenza test.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm","title":"QUEST DIAGNOSTICS INC 10-K (2026-02-26)","title_en":"QUEST DIAGNOSTICS INC 10-K (2026-02-26)","excerpt":"CDC 대비계약을 바탕으로 H5 조류인플루엔자 검사를 출시했다.","excerpt_en":"based on a preparedness contract from the CDC."},{"stance":"confirms","publisher":"미국 질병통제예방센터","publisher_en":"U.S. Centers for Disease Control and Prevention","kind":"ir","lang":"en","published_at":"2025-04-23","url":"https://www.cdc.gov/data-modernization/php/stories/cdc-streamlines-access-to-clinical-laboratory-data.html","title":"CDC Streamlines Access to Clinical Laboratory Data","title_en":"CDC Streamlines Access to Clinical Laboratory Data","excerpt":"CDC는 2024년 9월 퀘스트를 포함한 검사기관에 5년 계약을 발주했다.","excerpt_en":"CDC awarded five-year contracts to multiple laboratory companies."},{"stance":"mentions","publisher":"한국보건산업진흥원","publisher_en":"Korea Health Industry Development Institute","kind":"analysis","lang":"ko","published_at":"2022-11-28","url":"https://www.khepi.or.kr/ace/boardDownload.es?bid=0017&list_no=955&seq=1","title":"글로벌 보건산업 동향 Vol. 455","title_en":"Global Healthcare Industry Trends, Vol. 455","excerpt":"퀘스트가 독감과 COVID-19를 동시에 진단하는 기술을 개발했다고 소개했다.","excerpt_en":"Quest developed a method to diagnose influenza and COVID-19 viruses simultaneously."}]},{"direction":"cost","counterparty":"Epic Systems","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2025-09-23","basis":"Project Nova에서 Epic에 귀속되는 기술·서비스 구매액","value":null,"period":"multi-year Project Nova implementation","basis_en":"Project Nova technology and services spending attributable to Epic","qualifier":"confirmed_no_disclosed_value"},"note":"Epic은 퀘스트의 주문·검사결과·예약·청구 시스템을 통합하는 Project Nova에 기술과 서비스를 공급한다. 10-K는 Epic을 제3자 라이선스 제공자로 확인하지만 Epic에 귀속되는 계약금액은 따로 공개하지 않았다.","note_en":"Epic supplies technology and services for Project Nova, which consolidates Quest's ordering, results, scheduling, billing, and customer-service systems. The 10-K identifies Epic as a third-party licensor, but the amount payable specifically to Epic is not disclosed.","sources":[{"stance":"confirms","publisher":"Quest Diagnostics","publisher_en":"Quest Diagnostics","kind":"ir","lang":"en","published_at":"2025-09-23","url":"https://ir.questdiagnostics.com/press-releases/press-release-details/2025/Quest-Diagnostics-to-Improve-Laboratory-Testing-Experience-with-Industry-First-Epic-Collaboration/default.aspx","title":"Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration","title_en":"Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration","excerpt":"Epic은 Project Nova의 기반이 될 기술과 서비스를 퀘스트에 제공한다.","excerpt_en":"Epic will work with Quest to deliver a suite of technologies and services."}]},{"direction":"cost","counterparty":"지멘스","counterparty_slug":"siemens-ag","confidence":"mid","metric":{"type":"amount","unit":"USD","as_of":"2020-02-04","basis":"Siemens Healthineers 면역검사 장비·서비스 구매액","value":null,"period":"multi-year agreement announced 2020","basis_en":"Purchases of Siemens Healthineers immunoassay instruments and related services","qualifier":"confirmed_no_disclosed_value"},"note":"지멘스 계열 Siemens Healthineers는 퀘스트의 면역검사 우선 공급사로 선정돼 미국 19개 핵심·전문 검사실에 최대 120대의 Atellica 분석기를 배치하는 다년 계약을 발표했다. 상대별 구매액은 공개되지 않았다.","note_en":"Siemens Healthineers, part of Siemens, was selected as Quest's preferred immunoassay supplier under a multi-year agreement covering up to 120 Atellica analyzers across 19 U.S. core and esoteric laboratories. Supplier-specific spending was not disclosed.","sources":[{"stance":"confirms","publisher":"Siemens Healthineers","publisher_en":"Siemens Healthineers","kind":"ir","lang":"en","published_at":"2020-02-04","url":"https://www.siemens-healthineers.com/press/releases/pr-atellica-quest-diagnostics.html","title":"Siemens Healthineers Wins Bid to Become Primary Supplier for Quest Diagnostics Immunoassay Testing","title_en":"Siemens Healthineers Wins Bid to Become Primary Supplier for Quest Diagnostics Immunoassay Testing","excerpt":"Siemens Healthineers가 퀘스트의 면역검사 우선 공급사로 선정됐다.","excerpt_en":"selected by Quest Diagnostics to be its preferred supplier for immunoassay testing."}]}]}